United States - English - NLM (National Library of Medicine)

alvogen, inc - gadopentetate dimeglumine (unii: rh248g8v27) (gadopentetate - unii:v7ok6j19hq) - gadopentetate dimeglumine 469.01 mg in 1 ml - gadopentetate dimeglumine injection is indicated for use with magnetic resonance imaging (mri) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. gadopentetate dimeglumine injection has been shown to facilitate visualization of intracranial lesions including but not limited to tumors. gadopentetate dimeglumine is indicated for use with mri in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the head and neck. gadopentetate dimeglumine injection is indicated for use in mri in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart). gadopentetate dimeglumine is contraindicated in patients with:

United States - English - NLM (National Library of Medicine)

alvogen, inc - gadopentetate dimeglumine (unii: rh248g8v27) (gadopentetate - unii:v7ok6j19hq) - gadopentetate dimeglumine injection is indicated for use with magnetic resonance imaging (mri) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. gadopentetate dimeglumine injection has been shown to facilitate visualization of intracranial lesions including but not limited to tumors. gadopentetate dimeglumine is indicated for use with mri in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the head and neck. gadopentetate dimeglumine injection is indicated for use in mri in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart). gadopentetate dimeglumine injection is contraindicated in patients with:

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: pentetate meglumine; water for injections; meglumine - using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement: . in intracranial and spinal lesions in adults and children with abnormal blood-brain barrier, or abnormal vascularity; . in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis). indications as at 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients, including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pan

United States - English - NLM (National Library of Medicine)

hameln pharma gmbh - pentetate calcium trisodium (unii: g79yn26h5b) (pentetic acid - unii:7a314hqm0i) - pentetate calcium trisodium 1000 mg in 5 ml - ca-dtpa is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. none. pregnancy category c risk summary there are no adequate and well-controlled studies of ca-dtpa use in pregnant women. ca-dtpa chelation therapy causes depletion of body stores of zinc, a trace metal essential for fetal development [see warnings and precautions (5.2)] . the consequences of zinc depletion and results of animal studies suggest a teratogenic risk in humans. ca-dtpa was teratogenic and embryotoxic in mice at daily doses 2 to 8 times the recommended daily human dose, based on body surface area (bsa), with a dose-dependent increase in the frequency of gross malformations. ca-dtpa was teratogenic in dogs at approximately half the recommended daily human dose based on bsa, as described below. there are no animal or human data evaluating the teratogenic effect of a single dose of ca-dtpa. ca-dtpa should be used during pregnancy

United States - English - NLM (National Library of Medicine)

hameln pharma gmbh - pentetate zinc trisodium (unii: nxu65ic8pg) (pentetic acid - unii:7a314hqm0i) - pentetate zinc trisodium 1000 mg in 5 ml - zn-dtpa is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. none. pregnancy category b risk summary there are no adequate and well-controlled studies of zn-dtpa use in pregnant women. chelation treatment of pregnant women should begin and continue with zn-dtpa. reproduction studies have been performed in pregnant mice at doses up to 31 times (11.5 mmol/kg) the recommended daily human dose and have revealed no evidence of impaired fertility or harm to the fetus due to zn-dtpa. there was a slight reduction in the average birth weight. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. it is not known whether zn-dtpa is excreted in human milk. radiocontaminants are known to be excreted in breast milk. women with known or suspected internal contamination with radiocontaminants should not breast feed, whether